Since the first antibody domain (Caplacizumab) was approved by the FDA in 2019, VH antibody domains have been widely discussed for their multiple advantages over traditional antibodies, including the smaller size, reduced immunogenicity (fewer epitopes), relatively low cost of manufacturing, stability, flexibility of administration and better penetration to solid tumors. Antibody domains have multiple applications, such as designing as CARs or domain drug conjugates (DDCs), or bi-specific T cell or NK cell engagers (biTE/biKE). Antibody domains can be isolated from large size of human antibody heavy chain variable domain (VH) libraries or single B cell sorting and cloning from immunized camelids. Up to date, a wide variety of antibody domains have been developed for both tumor and viral targets. These antibody domain based therapeutics have played a significant role in patients with a broad spectrum of diseases.
Our goal for this research topic aims to provide a platform for peer-reviewed studies of therapeutic antibody domains in both clinical and research fields, to discuss the druggability, approaches of administration, and to address the question of whether antibody domains can play unique roles that cannot be achieved by traditional antibodies.
We welcome submissions of Original Research (basic studies, clinical studies) and Review articles as well as Opinions on recent advances in our understanding of domain antibody therapeutics against cancer. Topics may include, but are not limited to:
1. Identification of novel antibody domains against tumor targets for the development of therapeutics.
2. Studies of domain antibody engineering and evaluations of its druggability and developability, immunogenicity and other clinical-relevant characteristics.
3. Investigations of domain antibody novel administration routes, bio-distributions, pharmacokinetics in serum and tissues and penetration of solid tumors in different preclinical tumor models.
4. Pre-clinical studies of therapeutic efficacies of domain antibody based therapeutic modalities including bispecific antibodies, CAR-T cells, CAR-NK cells and domain antibody drug conjugates in various solid tumor models.
5. Clinical studies (PK and PD) of antibody domains as drug candidates for cancer therapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Topic Editor Dimiter S Dimitrov is the founder and CSO of Abound Bio. and declares no competing interests with regards to the Research Topic Subject.
Topic Editor Wei Li and Qi Zhao holds sets of patents about antibody against cancer and viral targets and declare no competing interests with regards to the Research Topic Subject.
All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Since the first antibody domain (Caplacizumab) was approved by the FDA in 2019, VH antibody domains have been widely discussed for their multiple advantages over traditional antibodies, including the smaller size, reduced immunogenicity (fewer epitopes), relatively low cost of manufacturing, stability, flexibility of administration and better penetration to solid tumors. Antibody domains have multiple applications, such as designing as CARs or domain drug conjugates (DDCs), or bi-specific T cell or NK cell engagers (biTE/biKE). Antibody domains can be isolated from large size of human antibody heavy chain variable domain (VH) libraries or single B cell sorting and cloning from immunized camelids. Up to date, a wide variety of antibody domains have been developed for both tumor and viral targets. These antibody domain based therapeutics have played a significant role in patients with a broad spectrum of diseases.
Our goal for this research topic aims to provide a platform for peer-reviewed studies of therapeutic antibody domains in both clinical and research fields, to discuss the druggability, approaches of administration, and to address the question of whether antibody domains can play unique roles that cannot be achieved by traditional antibodies.
We welcome submissions of Original Research (basic studies, clinical studies) and Review articles as well as Opinions on recent advances in our understanding of domain antibody therapeutics against cancer. Topics may include, but are not limited to:
1. Identification of novel antibody domains against tumor targets for the development of therapeutics.
2. Studies of domain antibody engineering and evaluations of its druggability and developability, immunogenicity and other clinical-relevant characteristics.
3. Investigations of domain antibody novel administration routes, bio-distributions, pharmacokinetics in serum and tissues and penetration of solid tumors in different preclinical tumor models.
4. Pre-clinical studies of therapeutic efficacies of domain antibody based therapeutic modalities including bispecific antibodies, CAR-T cells, CAR-NK cells and domain antibody drug conjugates in various solid tumor models.
5. Clinical studies (PK and PD) of antibody domains as drug candidates for cancer therapy.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Topic Editor Dimiter S Dimitrov is the founder and CSO of Abound Bio. and declares no competing interests with regards to the Research Topic Subject.
Topic Editor Wei Li and Qi Zhao holds sets of patents about antibody against cancer and viral targets and declare no competing interests with regards to the Research Topic Subject.
All other Topic Editors declare no competing interests with regards to the Research Topic subject.
